Pharmacokinetic, bioavailability, metabolism and plasma protein binding evaluation of NADPH-oxidase inhibitor apocynin using LC-MS/MS

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 985, Issue , 2015, Pages 180-188

  Chandasana, Hardik ^a,b   Chhonker, Yashpal S ^a,b   Bala, Veenu ^a,b   Prasad, Yarra D ^a,c   Chaitanya, Telaprolu K ^a,c   Sharma, Vishnu L ^a,b   Bhatta, Rabi S ^a,b,c  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^c National Institute of Pharmaceutical Education and Research (NIPER)   (India)

Author keywords

Apocynin; Diapocynin; HPLC MS MS; NADPH oxidase inhibitor; Pharmacokinetics

Indexed keywords

BIOCHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OXYGEN; PHARMACOKINETICS; PLASMA (HUMAN); PROTEINS; RATS;

ANTI-INFLAMMATORY ACTIVITY; ANTI-INFLAMMATORY DRUGS; APOCYNIN; DIAPOCYNIN; HPLC-MS/MS; NADPH OXIDASE; PHARMACOKINETIC PROFILES; PLASMA PROTEIN BINDING;

ENZYME INHIBITION;

ANTIINFLAMMATORY AGENT; APOCYNIN; DIAPOCYNIN; DRUG METABOLITE; UNCLASSIFIED DRUG; VERAPAMIL; ACETOPHENONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE PH; LIMIT OF QUANTITATION; LIVER CLEARANCE; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; STOMACH PH; TANDEM MASS SPECTROMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BLOOD; CHEMISTRY; LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT; STATISTICAL MODEL;

PICRORHIZA KURROOA; RATTUS;

ACETOPHENONES; ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; LINEAR MODELS; MALE; MICROSOMES, LIVER; NADPH OXIDASE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84922740087     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2015.01.025     Document Type: Article

References (23)

1. Hougee S., Hartog A., Sanders A., Graus Y.M., Hoijer M.A., Garssen J., van den Berg W.B., van Beuningen H.M., Smit H.F. Eur. J. Pharmacol. 2006, 531:264-269.
2. Kinoshita H., Matsumura T., Ishii N., Fukuda K., Senokuchi T., Motoshima H., Kondo T., Taketa K., Kawasaki S., Hanatani S., Takeya M., Nishikawa T., Araki E. Biochem. Biophys. Res. Commun. 2013, 431:124-130.
3. Muller A.A., Reiter S.A., Heider K.G., Wagner H. Planta Med. 1999, 65:590-594.
4. Tang X.N., Cairns B., Cairns N., Yenari M.A. Neuroscience 2008, 154:556-562.
5. Lin J.H., Lu A.Y. Pharmacol. Rev. 1997, 49:403-449.
6. Kumar G.N., Surapaneni S. Med. Res. Rev. 2001, 21:397-411.
7. Palmer A.M. Drug News Perspect. 2003, 16:57-62.
8. Roberts S.A. Curr. Opin. Drug Discov. Dev. 2003, 6:66-80.
9. Ximenes V.F., Kanegae M.P., Rissato S.R., Galhiane M.S. Arch. Biochem. Biophys. 2007, 457:134-141.
10. Wang Q., Smith R.E., Luchtefeld R., Sun A.Y., Simonyi A., Luo R., Sun G.Y. Phytomed. Int. J. Phytother. Phytopharmacol. 2008, 15:496-503.
11. Wang K., Li L., Song Y., Ye X., Fu S., Jiang J., Li S. PLOS ONE 2013, 8:e70189.
12. Luchtefeld R., Luo R., Stine K., Alt M.L., Chernovitz P.A., Smith R.E. J. Agric. Food Chem. 2008, 56:301-306.
13. Chandasana Y.S.C.H., Bala V., Prasad Y.D., Sharma V.L., Bhatta R.S. Anal. Methods Adv. Methods Appl. 2014, 7075-7082.
14. U. FDA, Guidelines for industry: Bioanalytical method validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation And Research Center (CDER) (2001). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
15. Kinkade K., Streeter J., Miller F.J. Int. J. Mol. Sci. 2013, 14:17017-17028.
16. Marques L.M., da Silva E.A., Gouvea D.R., Vessecchi R., Pupo M.T., Lopes N.P., Kato M.J., de Oliveira A.R. J. Pharm. Biomed. Anal. 2014, 95:113-120.
17. Baarnhielm C., Dahlback H., Skanberg I. Acta Pharmacol. Toxicol. (Copenh.) 1986, 59:113-122.
18. Smith R., Jones R.D., Ballard P.G., Griffiths H.H. Xenobiotica 2008, 38:1386-1398.
19. Liu Y., Davidson B.P., Yue Q., Belcik T., Xie A., Inaba Y., McCarty O.J., Tormoen G.W., Zhao Y., Ruggeri Z.M., Kaufmann B.A., Lindner J.R. Circ. Cardiovasc. Imaging 2013, 6:74-82.
20. Zamek-Gliszczynski M.J., Ruterbories K.J., Ajamie R.T., Wickremsinhe E.R., Pothuri L., Rao M.V., Basavanakatti V.N., Pinjari J., Ramanathan V.K., Chaudhary A.K. J. Pharm. Sci. 2011, 100:2498-2507.
21. Pelkonen O., Turpeinen M., Uusitalo J., Rautio A., Raunio H. Basic Clin. Pharmacol. Toxicol. 2005, 96:167-175.
22. Howard M.L., Hill J.J., Galluppi G.R., McLean M.A. Comb. Chem. High Throughput Screen. 2010, 13:170-187.
23. Trainor G.L. Expert Opin. Drug Discov. 2007, 2:51-64.